The controversy surrounding Covid-19’s origin continues to heat up, as the National Institutes of Health’s recent removal of genetic data about the novel coronavirus virus from the NIH archive was brought into the spotlight.

Data from Johns Hopkins University demonstrate that daily Covid-19 infections increased 316 percent from Labor Day 2020, or about four times more.

The number of coronavirus patients in U.S. hospitals breached 100,000, the highest level in eight months, according to the Department of Health and Human Services, as a resurgence of Covid-19 spurred by the highly contagious Delta variant strains the nation’s health care system.

The number of children hospitalized with Covid-19 in the United States hit a record high of more than 1,900 on Aug. 14, as hospitals across the South were stretched to capacity fighting outbreaks caused by the highly transmissible Delta variant.

The U.S. Food and Drug Administration on July 9 called for an independent federal probe into its representatives’ interactions with Biogen Inc. that led to approval of the company’s Alzheimer’s disease drug during June 2021.

Eric Lander, founding director of the Broad Institute of MIT and Harvard and science adviser for the White House, said in an interview that he wants to have an available vaccine that can fight the next pandemic in about 100 days after recognizing the initial outbreak.

The U.S. government will allot nearly 85 percent less Johnson & Johnson Covid-19 vaccines to states next week, data from Centers for Disease Control and Prevention (CDC) showed.

The United States put Johnson and Johnson in charge of a plant that ruined 15 million doses of the company’s Covid-19 vaccine and stopped British drugmaker AstraZeneca from using the facility, a senior health official said on April 3.

A U.S. Centers for Disease Control and Prevention study found that 2020 was the deadliest in U.S. history, with Covid-19 helping to drive a 15 percent increase in deaths, Politico reported on March 10, citing sources.

Merck logo

Merck entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/Covid-19 medicines and vaccines.